| (19) |
 |
|
(11) |
EP 2 351 742 A8 |
| (12) |
CORRECTED EUROPEAN PATENT APPLICATION |
|
published in accordance with Art. 153(4) EPC |
| (15) |
Correction information: |
|
Corrected version no 1 (W1 A1) |
| (48) |
Corrigendum issued on: |
|
21.09.2011 Bulletin 2011/38 |
| (43) |
Date of publication: |
|
03.08.2011 Bulletin 2011/31 |
| (22) |
Date of filing: 29.09.2009 |
|
| (51) |
International Patent Classification (IPC):
|
| (86) |
International application number: |
|
PCT/JP2009/066895 |
| (87) |
International publication number: |
|
WO 2010/041568 (15.04.2010 Gazette 2010/15) |
|
| (84) |
Designated Contracting States: |
|
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO SE SI SK SM TR |
| (30) |
Priority: |
09.10.2008 US 104024
|
| (71) |
Applicant: Asahi Kasei Pharma Corporation |
|
Tokyo 101-8101 (JP) |
|
| (72) |
Inventors: |
|
- NAKANO Seiji
Tokyo 101-8101 (JP)
- MORIMOTO Akifumi
Tokyo 101-8101 (JP)
- WADA Yasuhiro
Tokyo 101-8101 (JP)
|
| (74) |
Representative: Forstmeyer, Dietmar et al |
|
BOETERS & LIECK
Oberanger 32
80331 München
80331 München (DE) |
|
| |
|
(57) Compounds represented by the Formula (A-1) and the Formula (1) or salt thereof are
provided. The compounds represented by the Formula (A-1) and the Formula (1) or salt
thereof have a β3 adrenergic receptor agonist activity, and therefore are useful as
an agent for the prevention and treatment of diabetes, obesity, hyperlipidemia, depression,
biliary stone, a disorder derived from hyperactivity of biliary tract, a disorder
derived from hyperactivity of digestive tract, interstitial cystitis, overactive bladder,
urinary incontinence or a disorder derived from decreased tear secretion, etc.